DOJ recovered $2.5 billion in 2018 healthcare false claim cases
According to the DOJ, this is the ninth consecutive year that the organizations' civil healthcare fraud settlements and judgments have exceeded $2 billion.
Abbott Laboratories’ bittersweet week
Despite the week ending on a high note for Abbott Laboratories with an amended $5.3 billion deal to buy Alere, a warning letter from the U.S. Food and Drug Administration drew attention to issues at another Abbott acquisition — St. Jude Medical.
presented by
Transforming Patient Care: The Role of AI-Powered Assistants
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
In move to nix $5.8B Alere deal, is Abbott shrewdly aiming to lower price tag?
Abbott wants out of its plan to buy Alere for $5.8 billion, but the point-of-care testing company is a perfect fit for Abbott, an analyst believes.
Alere under Medicare/Medicaid fraud investigation (updated)
The investigation into potential fraud could put the brakes on the planned multibillion-dollar acquisition of Alere by Abbott Laboratories.
Morning Read: Sanofi makes $9.3B offer for Medivation, Alere says it rejected Abbott’s request to scrap M&A deal
Also, Color Genomics expands its genetic test portfolio and Apple rolls out first clinical apps developed with CareKit.
Abbott is on a roll with acquisitions – next on the list: Kalila Medical
Abbott is taking the new year by storm with two acquisitions in two days. We'll see what company will be snatched up next.
presented by
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Abbott agrees to put in nearly $6B to acquire Alere, broadening its diagnostics footprint
Abbott is looking to vastly expand its point-of-care diagnotics options by acquiring Alere.
Morning Read: Could Google searches help the FDA learn about drug side effects? ProNAi ‘s $138M IPO
Google met with FDA to discuss a paper on using search data to identify drug side effects and biotech company ProNAi has raised $138M in an IPO.
5 ways health IT companies are easing the transition from fee for service to pay for performance
As hospitals face increased pressure from the Affordable Care Act to move toward a reimbursement model centered in value-based outcomes integrated health systems are positioned to take advantage of some of the more sophisticated analytical tools to improve care coordination. There were an abundance of population health tools at HIMSS — from care coordination to […]